#FollowFriday @RussellRope #OG @WeedConnection
* READ & Click & READ & Click *
:: Creator @ WC @ RR Productions ::
:: Follow @RussellRope For Updates ::
:: Join The Revolution ::
:: Read & Take Action ::
:: True OG Stories @ RR ::
:: SUPREME #LegalTrillOG ::
----------------------------------
:: Media Marketing Services @ RRP ::
:: Connect | ADVERTISE | Work | Submit ::
:: Subscribe | Follow | Share | Like | Support ::
:: #FreeTheWeed @WeedConnection ::
#International #Business @WeedConnection
New WC Franchise in Development @ RRP OG LLC
All Advertising/Media Services Will Be Honored
10-50% DiScOuNt :: Connect / Select You Plan
. . . .
Ask about our current promotion, which is a free listing with purchase of any other service @WeedConnection. Recently started rebuilding our global database and added a new/temp delivery section to our directory. Send us an email to submit any current information. Click here for listing and advertising information. The directory is a huge project that requires maintenance. We still have big plans for future development and production. Join(t) the team as a regional manager, college intern, street team member, or click here for a list of other open positions. Support, subscribe, follow, share, like, and mention growing cannabis business @WeedConnection
#SocialMedia #Revolution @WeedConnection
#NORML #News @WeedConnection
Study: Cannabis Products Reduce Pain, Depression in Elderly Patients
Tel Aviv, Israel: The sustained use of pharmaceutical-grade cannabis products is associated with significant reductions in pain, depression, and opioid use among elderly patients, according to observational data published in the journal Biomedicines.
Israeli investigators assessed self-reported outcomes in a cohort of 119 elderly (mean age: 79) patients prescribed medical cannabis products. (Israeli law permits qualified patients to access state-regulated cannabis products, and an estimated 100,000 Israelis are currently authorized to use them.) Most of the study’s participants suffered from chronic pain and consumed cannabis via tinctures. Subjects utilized cannabis products for at least six months.
Authors reported that medical cannabis use was associated with clinically significant reductions in patients’ chronic pain scores. They also reported that patients reduced their use of opioids by nearly half following cannabis treatment – a finding consistent with other studies.
Cannabis use was also associated with reduced symptoms of depression and overall improvements in patients’ daily living, especially among those over the age of 80. The latter finding is consistent with several prior studies reporting health-related quality of life improvements among older adults who initiate cannabis treatment.
Researchers concluded: “Cannabis contributes to the amelioration of depressive symptoms …while also achieving discernible pain alleviation. … Our findings also demonstrate the relatively favorable safety profile of cannabis therapy” in the elderly patient population.
Full text of the study, “Medical cannabis is not associated with a decrease in activities of daily living in older adults,” appears in Biomedicines.
Analysis: Cannabis Use Common for Those Recuperating From Painful Work-Related Injuries
Toronto, Canada: Nearly one-quarter of Canadians with a painful work-related disability use cannabis during their recovery, according to data published in the Canadian Journal of Public Health.
Researchers affiliated with the University of Toronto surveyed 1,650 adults who were disabled due to a physical work injury or illness. They reported that 22.4 percent of those who suffered from a work-related injury that involved “severe pain symptoms” used cannabis as part of their treatment. (Cannabis is legal for both medical and adult-use in Canada.)
Overall, 11.5 percent of all disabled employees reported using cannabis “to manage conditions associated with the work-related injury,” a finding that is consistent with prior studies.
Those who used cannabis products to assist in their recovery generally did not differ from their non-using peers with respect to their disability expenditures or health care benefit expenses.
Authors concluded: “This study is one of a limited number of studies [assessing] the association between cannabis use and disability benefit expenditures in a representative sample of work disability episodes. The evidence presented in this study of working-age adults recovering from a work-related injury or illness does not find a substantial association of cannabis use with disability benefit expenditures and health care benefit expenditures that would suggest either concerning harm, or significant benefit. These findings contribute information to support decision making among clinicians and disability insurance authorities on the potential benefits and risks associated with cannabis use in settings that have legalized cannabis use.”
By contrast, US data reports declines in the number of workers’ compensation filings following the adoption of either medical cannabis legalization or adult-use legalization.
State courts in the United States have issued contradictory opinions regarding whether medical cannabis-related costs are eligible for reimbursement under workers’ compensation laws. Six states — Connecticut, New Hampshire, New Jersey, New Mexico, New York, and Pennsylvania -- currently allow for reimbursements. By contrast, seven states (Maine, Massachusetts, Minnesota, Florida, North Dakota, Ohio, and Washington) expressly prohibit workers’ compensation insurance from reimbursing medical marijuana-related costs. Other states are silent on the issue.
NORML’s Deputy Director Paul Armentano recently weighed in on the issue in an op-ed. He wrote:: “Most patients, most physicians, and most state laws view cannabis as a legitimate therapeutic option. Therefore, the millions of Americans who rely upon medical cannabis products ought to be afforded the same entitlements as those who use other conventional medications and therapies. Those privileges should include insurance-provided reimbursement for medical cannabis treatment.”
Full text of the study, “An observational study of pain severity, cannabis use, and benefit expenditures in work disability,” appears in the Canadian Journal of Public Health.
Survey: Health Providers Say They Are Unprepared To Discuss Cannabis Therapy With Their Cancer Patients
Toronto, Canada: Radiation therapists working in Canada, where the use of medical cannabis has been legal for more than two decades, acknowledge being unprepared to discuss the use of medical cannabis with their cancer patients, according to survey data published in the Journal of Medical Imaging and Radiation Sciences.
Investigators surveyed 282 radiation therapists. Just under one-fifth (19 percent) said that they frequently received inquiries from their patients about the use of medical cannabis. However, nearly 100 percent of those surveyed “believed that their radiation therapy training did not prepare them to support patients using cannabis.”
Authors concluded, “The findings of this study strongly advocate for the development of educational tools to meet Therapists clinical needs.”
Healthcare professionals in the United States and abroad – including nurses, pharmacists, clinicians, and nurse practitioners – consistently acknowledge that they are inadequately trained to counsel patients on matters specific to medical cannabis.
Survey data published in September reported that nearly one-third of US cancer patients turn to cannabis for symptom management, but most fail to inform their healthcar
e providers that they are using it.
Full text of the study, “Therapeutic cannabis use by patients with cancer in Canada: A national survey of the experiences, opinions, and information needs of Radiation Therapists,” appears in the Journal of Medical Imaging and Radiation Sciences.
#Invest @WeedConnection #Inc
#NORML #News @WeedConnection
Analysis: Marijuana Retailers Not Linked to Spikes in Crime
Washington, DC: The opening of state-licensed marijuana retailers does not negatively impact local crime rates, according to data published in the journal Annals of Regional Science.
Researchers with John Hopkins University and the University of Hawaii assessed the relationship between dispensary openings and neighborhood crime rates in Washington state’s three largest cities. Investigators reported that marijuana retailers “have a null effect on average local crime.”
They concluded: “Many North American jurisdictions have legalized the operation of recreational marijuana dispensaries. A common concern is that dispensaries may contribute to local crime. ... The random assignment of recreational marijuana retail licenses in Washington State provides a unique opportunity to identify the causal effect of dispensary openings on local crime. ... Combining lottery data with detailed geocoded crime data, we estimate that the presence of a dispensary has no significant impact on local crime in the average neighborhood.”
The findings are consistent with those of prior studies concluding that licensed marijuana retailers are typically associated with either no changes or decreases in criminal activity.
Full text of the study, “The impact of recreational marijuana dispensaries on crime: Evidence from a lottery experiment,” appears in Annals of Regional Science.
Clinical Trial: Nighttime Use of Cannabinol (CBN) Reduces Sleep Disturbances
Smith’s Falls, Canada: The oral consumption of the phytocannabinoid cannabinol (CBN) results in fewer sleep disturbances, according to placebo-controlled trial data published in the journal Experimental and Clinical Psychopharmacology.
Investigators assessed the use of CBN versus placebo in a cohort of 321 participants who self-rated their sleep quality as either “poor” or “very poor.” Subjects consumed either 20 mgs of CBN, a combined dosage of CBN and CBD, or placebo for seven days. Participants consumed cannabinoids in the form of gummies 90-minutes prior to bedtime.
The study’s authors reported, “Individuals receiving 20 mg CBN demonstrated reduced nighttime awakenings and overall sleep disturbance relative to placebo.” The combined use of CBD with CBN did not positively augment CBN treatment effects. Subjects reported only mild side-effects, including headache.
“The present study provides evidence to support the use of 20 mg CBN alone for the improvement of some sleep difficulties, including nighttime awakenings and overall sleep disturbance,” authors concluded. “[F]uture studies should continue to examine this potential side effects of CBN and compare it to the side effects of other pharmacological interventions for sleep.”
Prior placebo-controlled trials have reported that the use of cannabis extracts containing THC, CBD, and CBN is safe and effective for patients with chronic insomnia. Separate data published in 2018 also reported that the inhalation of herbal cannabis prior to bedtime is associated with “clinically significant improvements” in patients with insomnia.
Full text of the study, “A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality,” appears in Experimental and Clinical Psychopharmacology.
California: Governor Signs Bills Expanding Marijuana Rights for Patients, Employees
Sacramento, CA: Democratic Gov. Gavin Newsom signed a pair of bills into law expanding the rights of cannabis consumers.
The first bill, Senate Bill 302, permits qualified patients ages 65 and older to access certain cannabis products in private hospitals and other eligible health care facilities. The new law does not permit patients to either inhale or vaporize herbal cannabis in health care settings, and health care staff are forbidden from administering cannabis products. To date, a handful of states -- including Connecticut and Maine — have enacted legislation explicitly permitting the use of eligible cannabis products for hospitalized patients under certain circumstances.
The second bill, Senate Bill 700, makes it unlawful for employers to “request information from an applicant for employment relating to the applicant’s prior use of cannabis.” The legislation expands upon worker protections initially passed into law in 2022 making “it unlawful for an employer to discriminate against a person in hiring, termination, or any term or condition of employment, or otherwise penalize a person, if the discrimination is based upon the person’s use of cannabis off the job and away from the workplace.” Both worker protection laws take effect on January 1, 2024.
In recent years, numerous states – including Connecticut, Michigan, Minnesota, Montana, New Jersey, New York, Nevada, Rhode Island, and Washington – have passed legislation limiting the ability of employers to either refuse to hire and/or fire workers based solely upon their off-hours cannabis use.
Governor Newsom vetoed a third bill, AB 374, which sought to allow cannabis consumption facilities to serve patrons “non-cannabis food or beverage products” and to charge tickets to live performances. In his veto message, the Governor expressed concerns that the bill “could undermine California’s long-standing smoke-free workplace protections.”
Georgia: Regulators Move To Have Independent Pharmacies Provide State-Licensed Cannabis Products
Atlanta, GA: Regulators are moving forward with plans to permit the sale of state-licensed cannabis oil products in independently owned pharmacies.
The state’s Board of Pharmacy has begun accepting applications from licensed pharmacies that wish to supply low-THC/high-CBD cannabis extracts. The products have been legal to possess under state law since 2005. However, regulators failed to approve any licensed providers or dispensaries until earlier this year.
An estimated 120 independent pharmacies have reportedly agreed to carry the products. There are approximately 400 independent pharmacies operating in the state.
Chain drug stores will not be providing cannabis oil products.
About 14,000 Georgians are registered to access cannabis products for a variety of ailments, including autism, cancer, Crohn’s disease, seizure disorders, and Tourette’s syndrome.
Texas: Lubbock Advocates Reportedly Gather Nearly Twice as Many Signatures as Needed To Force Marijuana Depenalization Vote
Lubbock, Texas: Activists in the city of Lubbock (population: 261,000) have reportedly collected a sufficient number of signatures to compel city officials to vote on a measure depenalizing marijuana possession.
Advocates must submit 3,651 valid signatures from local voters by October 17th in order to place their initiated measure before politicians. Advocates say they have collected 8,800 signatures and that they plan to turn in some 10,000 signatures by the mid-October deadline.
The initiative seeks to end arrests and citations for adults who possess misdemeanor amounts of cannabis within the city’s limits. The measure also prohibits police from issuing citations for charges related to the possession of marijuana paraphernalia.
Once the signatures are certified, city officials will have to vote to either enact or reject the measure. If they reject it, the measure will go for before voters as a 2024 ballot initiative.
Voters in several Texas cities -- including Austin, Denton, Elgin, Harker Heights, Killeen, and San Marcos -- have approved similar ballot measures in recent years. In some instances, like in Harker Heights, local officials have attempted to halt the implementation of the measures following voter approval.
Information on the initiative effort is available from Freedom Act Lubbock.
#Advertise @WeedConnection
Media Services @RussellRope
#FollowFriday @RussellRope #OG @WeedConnection
* READ & Click & READ & Click *
:: Creator @ WC @ RR Productions ::
:: Follow @RussellRope For Updates ::
:: Join The Revolution ::
:: Read & Take Action ::
:: True OG Stories @ RR ::
:: SUPREME #LegalTrillOG ::
----------------------------------
:: Media Marketing Services @ RRP ::
:: Connect | ADVERTISE | Work | Submit ::
:: Subscribe | Follow | Share | Like | Support ::
:: #FreeTheWeed @WeedConnection ::
#NORML #News @WeedConnection
Study: No Significant Changes in Cannabis Use, Adverse Consequences Among High-Risk Young Adults Following Legalization
Hamilton, Canada: The adoption of cannabis legalization in Canada has not been associated with significant upticks in either marijuana use by young people or in the percentage of people experiencing adverse cannabis-related consequences, according to longitudinal data published in the journal JAMA Open Network.
A team of investigators from Canada and the United States assessed cannabis consumption trends in a cohort of at-risk young adults (ages 19 to 23) during the years immediately preceding and following legalization. Canada legalized the use and retail sale of marijuana products to those ages 18 and older in 2018.
Researchers reported, “Individuals who used cannabis more frequently pre-legalization significantly decreased their use and cannabis-related consequences post-legalization.” By contrast, those who had no history of cannabis use prior to legalization typically reported engaging in the limited use of marijuana use following legalization. However, this use was not associated with adverse consequences.
Authors concluded: “This study examined changes in cannabis use and consequences following recreational cannabis legalization in Canada in a sample of high-risk young adults, addressing the common concern that legalization may precipitate increases in use, particularly in this age group. Rather than detecting increases, however, the results revealed decreases overall, which is broadly consistent with substance use trajectories that might be expected among this age group in the absence of any policy change. … This study aligns with research from US jurisdictions which have largely found that legalization has not drastically altered consumption patterns among youths and young adults.”
State and federal data from the United States consistently has reported overall declines in self-reported marijuana use by young people over the past decade. During that time, nearly half of all states have adopted adult-use marijuana legalization.
Full text of the study, “Cannabis use frequency and cannabis-related consequences in high-risk young adults across cannabis legalization,” appears in JAMA Network Open.
Studies: One in Six Cancer Patients Report Using Cannabis for Symptom Management
Columbus, OH: Some 15 percent of cancer patients acknowledge consuming cannabis for symptom management, according to a pair of recent surveys.
The first study, published in the International Journal of Radiation Oncology, Biology, and Physics, surveyed nearly 2,500 patients receiving radiation for breast cancer. Fifteen percent of subjects acknowledged having used cannabis within the past 30 days. Patients most frequently endorsed using cannabis to treat insomnia, anxiety, and pain.
The second study, published in the journal Cancer Research Communications, surveyed 934 patients diagnosed with a variety of cancers. Just over 15 percent of respondents identified as current cannabis consumers. Patients most frequently reported consuming cannabis to mitigate pain, stress, and nausea, as well as to improve sleep and appetite. Cancer patients reported “moderate-high perceived effectiveness of cannabis-product use for symptom management.”
Authors of the study concluded, “Clinicians should be aware that a substantial percentage of patients with cancer are using cannabis products and report experiencing symptom relief with its use.”
The surveys’ findings are consistent with those of other studies concluding that cancer patients often turn to cannabis to alleviate their symptoms. However, despite the growing use of marijuana among cancer patients, most oncologists report receiving no “formal training regarding medical cannabis.”
Full text of the study, “Cannabis use patterns among patients with early-stage breast cancer in a large multicenter cohort from a state with legalized adult non-medical cannabis,” appears in the International Journal of Radiation Oncology, Biology, and Physics. Full text of the second study, “Marijuana and cannabidiol use prevalence and symptom management among patients with cancer,” appears in Cancer Research Communications.
Analysis: Most MS Patients Experience Less Spasticity Following Cannabis Treatment
Catania, Italy: Some 80 percent of multiple sclerosis (MS) patients suffering from severe spasticity experience dramatic reductions in their symptoms following treatment with a proprietary cannabis spray (aka Sativex) containing near equal rations of THC and CBD, according to an analysis of clinical trial data published in the journal Therapeutic Advancements in Neurological Disorders.
A team of Italian researchers analyzed trial data from three studies involving over 2,300 patients. They reported, “In all three studies, over 80 percent of assessed patients with severe spasticity at baseline reported a shift into a lower category of spasticity after 12 weeks.” This shift was most dramatic in those patients suffering from “severe spasticity” at baseline.
Sativex is available as a prescription medication in a number of countries, including Canada, France, Germany, Spain, and the United Kingdom. It is not approved for treatment in the United States. A separate cannabis extract drug, Epidiolex, which primarily contains CBD, is FDA-approved for the treatment of pediatric seizures.
Full text of the study, “A post hoc evaluation of the shift in spasticity in individuals with multiple sclerosis-related spasticity treated with nabiximols,” appears in Therapeutic Advancements in Neurological Disorders.
Analysis: Drug Sniffing Dogs Typically False Alert
Sydney, Australia: Drug sniffing dogs provide false alerts approximately seventy-five percent of the time, according to an analysis of ten years of data recently provided to members of the Australian Parliament.
The analysis reviewed over 94,000 searches. The overwhelming majority of those searches failed to identify the presence of illegal substances.
According to reporting in The Sydney Morning Herald, “The worst year for drug-detection dogs was 2014, when only 21 percent of the 14,213 searches resulted in illicit drugs being found; the best was two years later in 2016, where 32.5 percent of the 8746 searches were accurate.”
The findings of the analysis are consistent with those of prior studies. An analysis conducted by reporters at The Chicago Tribune similarly reported that drug sniffing dogs false-alerted over half of time, and that they were most likely to do so in instances where the suspect was Latino. Another study, this one published in the journal Animal Cognition, reported that drug dogs frequently falsely alert when their handlers perceive that illicit substances are present. “Handler beliefs affect outcomes of scent detection dog deployments,” the study’s authors concluded.
Nonetheless, the US Supreme Court has previously ruled that an alert from a police dog during a traffic stop provides a constitutional basis for law enforcement to search the interior of the vehicle.









